MIRA Pharmaceuticals completed dosing in its Phase 1 clinical trial evaluating Ketamir-2, a proprietary selective oral NMDA receptor modulator, in healthy volunteers. The randomized, double-blind, placebo-controlled study enrolled 56 healthy adult volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Based on safety data reviewed to date, no serious adverse events or dose-limiting toxicities have been reported at any dose level tested. No clinically significant dissociative or psychotomimetic effects typically associated with ketamine were observed. Database lock, unblinding, and final audited pharmacokinetic and safety analyses are currently underway. The company intends to submit the Phase 2a clinical study and supporting documentation to the U.S. Food and Drug Administration (FDA) under its active Investigational New Drug application in the first half of 2026. The planned Phase 2a proof-of-concept study is expected to enroll patients with moderate to severe chemotherapy-induced peripheral neuropathy (CIPN). MIRA Pharmaceuticals plans to present Phase 1 data at an upcoming scientific meeting.